Protein deregulation associated with breast cancer metastasis

Ka Kui Chan, Kyle B Matchett, Paul M McEnhill, el H Dakir, Mary Frances McMullin, Yahia El-Tanani, Laurence Patterson, Ahmed Faheem, Philip S Rudland, Paul A McCarron, Mohamed El-Tanani

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Breast cancer is one of the most prevalent malignancies worldwide. It consists of a group of tumor cells that have the ability to grow uncontrollably, overcome replicative senescence (tumor progression) and metastasize within the body. Metastases are processes that consist of an array of complex gene dysregulation events. Although these processes are still not fully understood, the dysregulation of a number of key proteins must take place if the tumor cells are to disseminate and metastasize. It is now widely accepted that future effective and innovative treatments of cancer metastasis will have to encompass all the major components of malignant transformation. For this reason, much research is now being carried out into the mechanisms that govern the malignant transformation processes. Recent research has identified key genes involved in the development of metastases, as well as their mechanisms of action. A detailed understanding of the encoded proteins and their interrelationship generates the possibility of developing novel therapeutic approaches. This review will focus on a select group of proteins, often deregulated in breast cancer metastasis, which have shown therapeutic promise, notably, EMT, E-cadherin, Osteopontin, PEA3, Transforming Growth Factor Beta (TGF-β) and Ran.

Original languageEnglish
Pages (from-to)415-23
Number of pages9
JournalCytokine & Growth Factor Reviews
Issue number4
Early online date31 May 2015
Publication statusPublished - Aug 2015


Dive into the research topics of 'Protein deregulation associated with breast cancer metastasis'. Together they form a unique fingerprint.

Cite this